Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow: 2021-2025

Historic Net Cash Flow for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to -$17.2 million.

  • Kiniksa Pharmaceuticals International's Net Cash Flow fell 806.54% to -$17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.5 million, marking a year-over-year increase of 478.85%. This contributed to the annual value of $75.6 million for FY2024, which is 612.34% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Net Cash Flow stood at -$17.2 million for Q3 2025, which was down 149.22% from $34.9 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Net Cash Flow peaked at $86.2 million during Q4 2024, and registered a low of -$67.7 million during Q4 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median Net Cash Flow value was -$1.9 million (recorded in 2024), while the average stood at $4.7 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first plummeted by 1,116.60% in 2022, then surged by 973.05% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Net Cash Flow (Quarterly) stood at -$67.7 million in 2021, then climbed by 21.66% to -$53.0 million in 2022, then spiked by 81.39% to -$9.9 million in 2023, then spiked by 973.05% to $86.2 million in 2024, then slumped by 806.54% to -$17.2 million in 2025.
  • Its last three reported values are -$17.2 million in Q3 2025, $34.9 million for Q2 2025, and -$26.4 million during Q1 2025.